1. Fuentes, N. R. et al. Membrane therapy using DHA suppresses epidermal growth factor receptor signaling by disrupting nanocluster formation. J Lipid Res 62, 100026, (2021).
  2. Li, J. et al. Assessing the safety of transarterial locoregional delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat liver. Eur J Pharm Biopharm 158, 273-283, (2021).
  3. Wang, Y. et al. An implanted port-catheter system for repeated hepatic arterial infusion of low-density lipoprotein-docosahexaenoic acid nanoparticles in normal rats: A safety study. Toxicol Appl Pharmacol 400, 115037, (2020).
  4. Lee, M. H., Malloy, C. R., Corbin, I. R., Li, J. & Jin, E. S. Assessing the pentose phosphate pathway using [2, 3-(13) C(2) ]glucose. NMR Biomed 32, e4096, (2019).
  5. Chaudhary, J., Bower, J. & Corbin, I. R. Lipoprotein Drug Delivery Vehicles for Cancer: Rationale and Reason. Int J Mol Sci 20, (2019).
  6. Lee, M. H. et al. Active pyruvate dehydrogenase and impaired gluconeogenesis in orthotopic hepatomas of rats. Metabolism 101, 153993, (2019).
  7. Sutphin, P. D., Lamus, D., Kalva, S. P., Li, J. & Corbin, I. R. in Hepatocellular Carcinoma: Translational Precision Medicine Approaches (ed Y. Hoshida) 169-194 (2019).
  8. Ou, W. et al. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma. Free Radic Biol Med 112, 597-607 (2017).
  9. Mulik, R.S. et al. Elucidating the structural organization of a novel low-density lipoprotein nanoparticle reconstituted with docosahexaenoic acid. Chem Phys Lipids 204, 65-75 (2017).
  10. Wen, X. et al. Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. Gastroenterology 150, 488-498 (2016).
  11. Satapati, S. et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest 126, 1605 (2016).
  12. Mulik, R.S. et al. Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. Biomaterials 83, 257-268 (2016).
  13. Moss, L.R., Mulik, R.S., Van Treuren, T., Kim, S.Y. & Corbin, I.R. Investigation into the distinct subcellular effects of docosahexaenoic acid loaded low-density lipoprotein nanoparticles in normal and malignant murine liver cells. Biochim Biophys Acta 1860, 2363-2376 (2016).
  14. Reynolds, L., Mulik, R.S., Wen, X., Dilip, A. & Corbin, I.R. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine (Lond) 9, 2123-2141 (2014).
  15. Corbin, I.R., Ng, K.K., Ding, L., Jurisicova, A. & Zheng, G. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond) 8, 875-890 (2013).
  16. Corbin, I.R. Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol Biol 1049, 467-480 (2013).
  17. McKee, T.D., Chen, J., Corbin, I., Zheng, G. & Khokha, R. Quantifying Nanoparticle Transport in Vivo Using Hyperspectral Imaging with a Dorsal Skinfold Window Chamber. J Innov Opt Health Sci 5 (2012).
  18. Marotta, D.E. et al. Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo. Nanomedicine (Lond) 6, 475-487 (2011).
  19. Zhang, Z. et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6, 430-437 (2010).
  20. Hill, M.L. et al. In vitro assessment of poly-iodinated triglyceride reconstituted low-density lipoprotein: initial steps toward CT molecular imaging. Acad Radiol 17, 1359-1365 (2010).
  21. Zhang, Z. et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 48, 9171-9175 (2009).
  22. Glickson, J.D. et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Adv Exp Med Biol 645, 227-239 (2009).
  23. Corbin, I.R., Furth, E.E., Pickup, S., Siegelman, E.S. & Delikatny, E.J. In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. Biochim Biophys Acta 1791, 757-763 (2009).
  24. Cao, W. et al. Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug Chem 20, 2023-2031 (2009).
  25. Glickson, J.D. et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol Imaging 7, 101-110 (2008).
  26. Watt, K., Kives, K., Corbin, I., Zhang, M. & Minuk, G.Y. Lack of susceptibility to ischemic necrosis of the remnant liver following partial hepatectomy in the rat. Hepatogastroenterology 54, 463-465 (2007).
  27. Song, L. et al. Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine 2, 767-774 (2007).
  28. Corbin, I.R. & Zheng, G. Mimicking nature's nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug delivery. Nanomedicine (Lond) 2, 375-380 (2007).
  29. Chen, J. et al. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc 129, 5798-5799 (2007).
  30. Zhang, M., Gong, Y., Corbin, I. & Minuk, G.Y. The effects of light and moderate-heavy ethanol exposure on the development of cirrhosis in rats. Dig Dis Sci 51, 1732-1737 (2006).
  31. Corbin, I.R. et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8, 488-498 (2006).
  32. Li, H. et al. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 11, 1251-1259 (2004).
  33. Corbin, I.R., Ryner, L.N., Singh, H. & Minuk, G.Y. Quantitative hepatic phosphorus-31 magnetic resonance spectroscopy in compensated and decompensated cirrhosis. Am J Physiol Gastrointest Liver Physiol 287, G379-384 (2004).
  34. Zhang, M., Uhanova, J., Corbin, I., Bernstein, C. & Minuk, G.Y. Effects of daily, light and moderate-heavy ethanol exposure on extent of hepatic injury and recovery following toxin-induced acute hepatitis in rats. Dig Dis Sci 48, 926-931 (2003).
  35. Corbin, I.R. & Minuk, G.Y. Serial percutaneous liver biopsies in laboratory rats. Dig Dis Sci 48, 1939-1943 (2003).
  36. Corbin, I.R. et al. Hepatic 31P MRS in rat models of chronic liver disease: assessing the extent and progression of disease. Gut 52, 1046-1053 (2003).
  37. Corbin, I.R. et al. Utility of hepatic phosphorus-31 magnetic resonance spectroscopy in a rat model of acute liver failure. J Investig Med 51, 42-49 (2003).
  38. Corbin, I.R., Gong, Y., Zhang, M. & Minuk, G.Y. Proliferative and nutritional dependent regulation of glyceraldehyde-3-phosphate dehydrogenase expression in the rat liver. Cell Prolif 35, 173-182 (2002).
  39. Corbin, I.R. et al. Regenerative activity and liver function following partial hepatectomy in the rat using (31)P-MR spectroscopy. Hepatology 36, 345-353 (2002).
  40. Zhang, M. et al. Light ethanol consumption enhances liver regeneration after partial hepatectomy in rats. Gastroenterology 119, 1333-1339 (2000).
  41. Corbin, I., Novak, M. & Blackburn, B.J. Changes in hepatic lipids of mice infected with cysticerci of Taenia crassiceps. J Helminthol 74, 209-214 (2000).
  42. Corbin, I., Simcoff, R., Novak, M. & Blackburn, B.J. Metabolism of [3-(13)C]-pyruvate by cysticerci of Taenia crassiceps. Parasitol Res 84, 516-518 (1998).
  43. Corbin, I., Blackburn, B.J., Wolowiec, T. & Novak, M. Metabolic profile of the liver of mice infected with cysticerci of Taenia crassiceps. Parasitol Res 82, 273-275 (1996).